Breast Cancer Heterogeneity

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2021 Sep 28

PMID 34573897

Citations 21

Authors

Caterina Fumagalli

Massimo Barberis

Affiliations

Soon will be listed here.

Abstract

Breast tumor heterogeneity is a major challenge in the clinical management of breast cancer patients. Both inter-tumor and intra-tumor heterogeneity imply that each breast cancer (BC) could have different prognosis and would benefit from specific therapy. Breast cancer is a dynamic entity, changing during tumor progression and metastatization and this poses fundamental issues to the feasibility of a personalized medicine approach. The most effective therapeutic strategy for patients with recurrent disease should be assessed evaluating biopsies obtained from metastatic sites. Furthermore, the tumor progression and the treatment response should be strictly followed and radiogenomics and liquid biopsy might be valuable tools to assess BC heterogeneity in a non-invasive way.

Citing Articles

A comprehensive bioinformatic evaluation of the NTRK family's potential as prognostic biomarkers in breast cancer.

Mohammadi R, Ghiasi M, Mehdizadeh S, Mohammadi J, Mohammad Ganji S Bioinform Adv. 2025; 5(1):vbaf030.

PMID: 40061872 PMC: 11886811. DOI: 10.1093/bioadv/vbaf030.

Biological correlates associated with high-risk breast cancer patients identified using a computational method.

Oh J, Pareja F, Elkin R, Xu K, Norton L, Deasy J NPJ Breast Cancer. 2025; 11(1):8.

PMID: 39875417 PMC: 11775240. DOI: 10.1038/s41523-025-00725-y.

Facilitation of Tumor Stroma-Targeted Therapy: Model Difficulty and Co-Culture Organoid Method.

Feng Q, Shan X, Yau V, Cai Z, Xie S Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861125 PMC: 11769033. DOI: 10.3390/ph18010062.

The clinicopathological significance of BRI3BP in women with invasive breast cancer.

Aljohani A, Aljahdali I, Alsalmi O, Alsuwat M, Alsharif A, Alzahrani K Transl Cancer Res. 2025; 13(12):6837-6849.

PMID: 39816562 PMC: 11730447. DOI: 10.21037/tcr-24-1113.

Prognostic Significance of DSCC1, a Biomarker Associated with Aggressive Features of Breast Cancer.

Aljohani A Medicina (Kaunas). 2025; 60(12.

PMID: 39768811 PMC: 11677291. DOI: 10.3390/medicina60121929.

References

Patani N, Barbashina V, Lambros M, Gauthier A, Mansour M, Mackay A . Direct evidence for concurrent morphological and genetic heterogeneity in an invasive ductal carcinoma of triple-negative phenotype. J Clin Pathol. 2011; 64(9):822-8. DOI: 10.1136/jclinpath-2011-200135. View

Gomez-Fernandez C, Daneshbod Y, Nassiri M, Milikowski C, Alvarez C, Nadji M . Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer. Am J Clin Pathol. 2008; 130(6):879-82. DOI: 10.1309/AJCPD1AO3YSYQYNW. View

De Santo I, McCartney A, Migliaccio I, Di Leo A, Malorni L . The Emerging Role of Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy. Cancers (Basel). 2019; 11(12). PMC: 6966519. DOI: 10.3390/cancers11121894. View

Seol H, Lee H, Choi Y, Lee H, Kim Y, Kim J . Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod Pathol. 2012; 25(7):938-48. DOI: 10.1038/modpathol.2012.36. View

Berben L, Wildiers H, Marcelis L, Antoranz A, Bosisio F, Hatse S . Computerised scoring protocol for identification and quantification of different immune cell populations in breast tumour regions by the use of QuPath software. Histopathology. 2020; 77(1):79-91. DOI: 10.1111/his.14108. View

Heselmeyer-Haddad K, Berroa Garcia L, Bradley A, Ortiz-Melendez C, Lee W, Christensen R . Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression. Am J Pathol. 2012; 181(5):1807-22. PMC: 3483801. DOI: 10.1016/j.ajpath.2012.07.012. View

Fumagalli C, Ranghiero A, Gandini S, Corso F, Taormina S, De Camilli E . Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses. Breast Cancer Res. 2020; 22(1):107. PMC: 7566144. DOI: 10.1186/s13058-020-01345-z. View

Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R . ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015; 12(10):573-83. PMC: 4911210. DOI: 10.1038/nrclinonc.2015.117. View

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G . The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2014; 26(2):259-71. PMC: 6267863. DOI: 10.1093/annonc/mdu450. View

10.

Young R, Louis D . The Warrens and other pioneering clinician pathologists of the Massachusetts General Hospital during its early years: an appreciation on the 200th anniversary of the hospital founding. Mod Pathol. 2011; 24(10):1285-94. DOI: 10.1038/modpathol.2011.132. View

11.

Fan M, Zhang P, Wang Y, Peng W, Wang S, Gao X . Radiomic analysis of imaging heterogeneity in tumours and the surrounding parenchyma based on unsupervised decomposition of DCE-MRI for predicting molecular subtypes of breast cancer. Eur Radiol. 2019; 29(8):4456-4467. DOI: 10.1007/s00330-018-5891-3. View

12.

Davis S, Eckhardt S, Tentler J, Diamond J . Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers. Ther Adv Med Oncol. 2014; 6(3):88-100. PMC: 3987651. DOI: 10.1177/1758834013519843. View

13.

Rossi L, Verrico M, Tomao S, Ricci F, Fontana A, Spinelli G . Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy. Cancer Chemother Pharmacol. 2019; 85(1):105-111. DOI: 10.1007/s00280-019-03981-5. View

14.

Guerini-Rocco E, Gray K, Fumagalli C, Reforgiato M, Leone I, Rafaniello Raviele P . Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial. Clin Cancer Res. 2020; 27(2):504-512. DOI: 10.1158/1078-0432.CCR-20-0126. View

15.

Denkert C, Liedtke C, Tutt A, von Minckwitz G . Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2016; 389(10087):2430-2442. DOI: 10.1016/S0140-6736(16)32454-0. View

16.

Yates L, Campbell P . Evolution of the cancer genome. Nat Rev Genet. 2012; 13(11):795-806. PMC: 3666082. DOI: 10.1038/nrg3317. View

17.

Aftimos P, Oliveira M, Irrthum A, Fumagalli D, Sotiriou C, Nili Gal-Yam E . Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. Cancer Discov. 2021; 11(11):2796-2811. PMC: 9414283. DOI: 10.1158/2159-8290.CD-20-1647. View

18.

Adams S, Gray R, Demaria S, Goldstein L, Perez E, Shulman L . Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014; 32(27):2959-66. PMC: 4162494. DOI: 10.1200/JCO.2013.55.0491. View

19.

Waks A, Cohen O, Kochupurakkal B, Kim D, Dunn C, Buendia Buendia J . Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer. Ann Oncol. 2020; 31(5):590-598. PMC: 7946408. DOI: 10.1016/j.annonc.2020.02.008. View

20.

Bruna A, Rueda O, Greenwood W, Batra A, Callari M, Batra R . A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell. 2016; 167(1):260-274.e22. PMC: 5037319. DOI: 10.1016/j.cell.2016.08.041. View